The use of adult stem cells for the purpose of tissue regeneration offers the opportunity to revolutionize treatment of a broad range of serious diseases affecting millions of patients.
ALDAGEN currently has three products in clinical testing:
- ALD-101 for pediatric metabolic disorders and malignancies (Phase I complete)
- ALD-201 for chronic heart failure (Phase I/II enrolling)
- ALD-301 for critical limb ischemia (Phase I/II enrolling)
ALDAGEN believes its technology can isolate cells populations from bone marrow and other sources that could be useful in the treatment of other diseases including neurodegenerative disorders, orthopedic applications, and diabetes.
